Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
*Correspondence: Angel Gil-Izquierdo, Campus de Espinardo-25, Murcia, Murcia, Spain e-mail: [email protected] This article was submitted to Nutrition and Food Science Technology, a section of the journal Frontiers in Nutrition
From injectable therapies to oral small-molecule drugs, the evolution of technology is reshaping industry supply chains, manufacturing models, and competitive dynamics
An augmented synthesis of NO fosters vasodilation, endothelial restoration, and enhanced blood circulation, thus mitigating the vascular rigidity and compromised perfusion typically associated with aging tissues
Diabetic ketoacidosis has been reported in insulin-dependent patients who began treatment with a GLP-1 receptor agonist and therefore had their insulin discontinued or their dose rapidly reduced
Key Regions and Countries North America US Canada Europe Germany France The UK Spain Italy Russia Netherland Rest of Europe Asia Pacific China Japan South Korea India Australia New Zealand Singapore Thailand Vietnam Rest of APAC Latin America Brazil Mexico Rest of Latin America Middle East & Africa South Africa Saudi Arabia UAE Rest of MEA Key Players Analysis The anti-obesity drugs market is currently dominated by two pharmaceutical giants: Novo Nordisk and Eli Lilly
10.3109/10428194.2014.893310 75 ShenoyS.EapenM.PanepintoJ
US$ 23.16
US$ 21.94
US$ 21.22
US$ 29.15
US$ 27.55
US$ 22.37
US$ 21.07
